AFM-Telethon financially supports IFB-088 regulatory long term toxicological studies in animals and clinical pharmacology in human for the treatment of CMT disease.

CMT patient associations

InFlectis BioScience is in connection with CMT patient associations in Europe (CMT-France and CMT-EUROPE) and in the USA (CMTA and HNF) to better understand the daily impact CMT has on a patients quality of life and to gain insight on what is most important to patients when thinking about drug development.

In addition, InFlectis BioScience in collaboration with CMT-France and CMT-EUROPE is carrying out a socio-economic study on CMT, to accurately elicit the impact of the disease on patient quality of life and evaluate the disease socio-economic burden.